Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Onxeo. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Onxeo's earnings available for a low price, and how does
this compare to other companies in the same industry?
Unable to determine if Onxeo is high growth as no earnings estimate data is available.
Unable to determine if Onxeo is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Onxeo's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Ms. Judith Greciet, Ph.D., Pharmacy, has been the Chief Executive Officer of Onxeo SA (alternate name BioAlliance Pharma) since June 29, 2011. Ms. Greciet served as the Chief Operations Officer - Operations and R&D at Onxeo SA since March 1, 2011. Ms. Greciet served as Deputy Chief Operating Officer of BioAlliance Pharma since March 2011. Ms. Greciet has an exemplary career in the pharmaceutical industry and international groups. Ms. Greciet joined Eisai France in June 2007 after successful achievements at Wyeth Pharmaceuticals France (today Pfizer), LFB Group (Laboratoire Francais du fractionnement et des Biotechnologies, a French bio-pharmaceutical company), Zeneca and Pharmacia, where she held increasing operational and strategic positions involving a managerial scope. She particularly focused on optimizing links with all health actors (researchers, academic practitioners, medical doctors, patient associations, health authorities.). She exercised her talents in the oncology and immunology areas with innovative products such as Enbrel (in rheumatology). She has served successively as Head of the Oncology Department and of the Hospital Department where she was notably in charge of hospital antibiotherapy projects. She has been a Director of Onxeo SA since June 29, 2011. She holds a Doctorate of Pharmacy in addition to being a graduate of 3(rd) cycle management and pharmaceutical marketing.
Judith's compensation has increased whilst company is loss making.
Judith's remuneration is higher than average for companies of similar size in France.
Management Team Tenure
Average tenure and age of the
management team in years:
The tenure for the Onxeo management team is about average.
CEO & Director
CFO & Administrative and Finance Director
Chief Scientific Officer
Director of Human Resources
Chief Pharmacist & Quality Assurance Director
Chief of US Operations & Executive VP
Olivier de Beaumont
Chief Medical Officer
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Onxeo board of directors is about average.
Does Onxeo SA (EPA:ONXEO) Have A Volatile Share Price?
If you're interested in Onxeo SA (EPA:ONXEO), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact your portfolio. … Some investors use beta as a measure of how much a certain stock is impacted by market risk (volatility). … A stock with a beta greater than one is more sensitive to broader market movements than a stock with a beta of less than one.
If You Had Bought Onxeo (EPA:ONXEO) Stock Five Years Ago, You'd Be Sitting On A 89% Loss, Today
For example, we sympathize with anyone who was caught holding Onxeo SA (EPA:ONXEO) during the five years that saw its share price drop a whopping 89%. … Onxeo isn't a profitable company, so it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). … In the last five years Onxeo saw its revenue shrink by 6.5% per year.
Does Onxeo SA's (EPA:ONXEO) CEO Salary Compare Well With Others?
This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. … How Does Judith Greciet's Compensation Compare With Similar Sized Companies. … We examined a group of similar sized companies, with market capitalizations of below €176m
Beta is a widely used metric to measure a stock's exposure to market risk (volatility). … A stock with a beta below one is either less volatile than the market, or more volatile but not corellated with the overall market. … In comparison a stock with a beta of over one tends to be move in a similar direction to the market in the long term, but with greater changes in price.
Here's What We Think About Onxeo SA's (EPA:ONXEO) CEO Pay
This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. … How Does Judith Greciet's Compensation Compare With Similar Sized Companies. … According to our data, Onxeo SA has a market capitalization of €46m, and pays its CEO total annual compensation worth €647k.
Analysts Expect Breakeven For Onxeo SA (EPA:ONXEO)
Onxeo SA's (EPA:ONXEO):. … Onxeo SA, a biotechnology company, develops drugs for the treatment of orphan oncology diseases worldwide. … Many investors are wondering the rate at which ONXEO will turn a profit, with the big question being “when will the company breakeven?”
ONXEO has high near term liquidity, with short term assets (cash and other liquid assets) amply covering upcoming one-year liabilities, as well as long-term commitments. … One reason I do like ONXEO as a business is its low level of fixed assets on its balance sheet (0.48% of total assets). … ONXEO has virtually no fixed assets, which minimizes its downside risk.
Onxeo SA, a biotechnology company, develops drugs for the treatment of orphan oncology diseases worldwide. The company offers Beleodaq for the treatment of relapsed or refractory peripheral T-cell lymphoma. It also develops AsiDNA, which is in clinical development stage for the treatment of metastatic melanoma; and Validive, which completed Phase II clinical trial for the treatment of serious mucositis in patients treated for a head and neck cancer. Onxeo SA has a collaboration and licensing agreement with Spectrum Pharmaceuticals for the development of Beleodaq; and a license agreement with Monopar Therapeutics Inc. to develop Validive. The company was formerly known as BioAlliance Pharma SA and changed its name to Onxeo SA in July 2014. Onxeo SA was founded in 1997 and is based in Paris, France.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.